1,10-Phenanthroline

Identification

Name
1,10-Phenanthroline
Accession Number
DB02365  (EXPT02592)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
NSC-203545 / NSC-4265
Categories
UNII
W4X6ZO7939
CAS number
66-71-7
Weight
Average: 180.2053
Monoisotopic: 180.068748266
Chemical Formula
C12H8N2
InChI Key
DGEZNRSVGBDHLK-UHFFFAOYSA-N
InChI
InChI=1S/C12H8N2/c1-3-9-5-6-10-4-2-8-14-12(10)11(9)13-7-1/h1-8H
IUPAC Name
1,10-phenanthroline
SMILES
C1=CC2=CC=C3C=CC=NC3=C2N=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UMethyl-accepting chemotaxis protein IINot AvailableSalmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
UMetallo-beta-lactamase L1Not AvailablePseudomonas maltophilia
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with 1,10-Phenanthroline.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational
Acebutolol1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with 1,10-Phenanthroline.Experimental, Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with 1,10-Phenanthroline.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with 1,10-Phenanthroline.Experimental, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with 1,10-Phenanthroline.Approved, Illicit, Investigational
Alprenolol1,10-Phenanthroline may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with 1,10-Phenanthroline.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with 1,10-Phenanthroline.Approved
AmikacinThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with 1,10-Phenanthroline.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with 1,10-Phenanthroline.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with 1,10-Phenanthroline.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with 1,10-Phenanthroline.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with 1,10-Phenanthroline.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with 1,10-Phenanthroline.Approved
ArecolineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Arecoline.Experimental
Arotinolol1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.Investigational
Asenapine1,10-Phenanthroline may increase the bradycardic activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with 1,10-Phenanthroline.Investigational
Atenolol1,10-Phenanthroline may increase the bradycardic activities of Atenolol.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with 1,10-Phenanthroline.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Vet Approved
Beclomethasone dipropionateThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Beclomethasone dipropionate.Approved, Investigational
Befunolol1,10-Phenanthroline may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with 1,10-Phenanthroline.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
Betaxolol1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Bethanechol.Approved
Bevantolol1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Bisoprolol1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Boceprevir.Approved, Withdrawn
Bopindolol1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
BrompheniramineThe therapeutic efficacy of Brompheniramine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Bucindolol1,10-Phenanthroline may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Budesonide.Approved
Bufuralol1,10-Phenanthroline may increase the bradycardic activities of Bufuralol.Experimental, Investigational
Bupranolol1,10-Phenanthroline may increase the bradycardic activities of Bupranolol.Approved
BupropionThe therapeutic efficacy of Bupropion can be decreased when used in combination with 1,10-Phenanthroline.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with 1,10-Phenanthroline.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Carbachol.Approved
Carteolol1,10-Phenanthroline may increase the bradycardic activities of Carteolol.Approved
Carvedilol1,10-Phenanthroline may increase the bradycardic activities of Carvedilol.Approved, Investigational
Celiprolol1,10-Phenanthroline may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with 1,10-Phenanthroline.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with 1,10-Phenanthroline.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with 1,10-Phenanthroline.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with 1,10-Phenanthroline.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
Cloranolol1,10-Phenanthroline may increase the bradycardic activities of Cloranolol.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with 1,10-Phenanthroline.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with 1,10-Phenanthroline.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with 1,10-Phenanthroline.Approved, Investigational
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with 1,10-Phenanthroline.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Cyclophosphamide.Approved, Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with 1,10-Phenanthroline.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with 1,10-Phenanthroline.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with 1,10-Phenanthroline.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with 1,10-Phenanthroline.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with 1,10-Phenanthroline.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with 1,10-Phenanthroline.Experimental, Vet Approved
DexamethasoneThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with 1,10-Phenanthroline.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with 1,10-Phenanthroline.Withdrawn
DextromethorphanThe therapeutic efficacy of Dextromethorphan can be decreased when used in combination with 1,10-Phenanthroline.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with 1,10-Phenanthroline.Experimental
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with 1,10-Phenanthroline.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with 1,10-Phenanthroline.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with 1,10-Phenanthroline.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with 1,10-Phenanthroline.Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Diphenhydramine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
DipyridamoleThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dipyridamole.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with 1,10-Phenanthroline.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
DoxylamineThe therapeutic efficacy of Doxylamine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Vet Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
Epanolol1,10-Phenanthroline may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with 1,10-Phenanthroline.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with 1,10-Phenanthroline.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with 1,10-Phenanthroline.Approved
Esatenolol1,10-Phenanthroline may increase the bradycardic activities of Esatenolol.Experimental
Esmolol1,10-Phenanthroline may increase the bradycardic activities of Esmolol.Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with 1,10-Phenanthroline.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with 1,10-Phenanthroline.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with 1,10-Phenanthroline.Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with 1,10-Phenanthroline.Approved
FlavoxateThe therapeutic efficacy of Flavoxate can be decreased when used in combination with 1,10-Phenanthroline.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with 1,10-Phenanthroline.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with 1,10-Phenanthroline.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with 1,10-Phenanthroline.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with 1,10-Phenanthroline.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with 1,10-Phenanthroline.Approved, Investigational
FluoxetineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with 1,10-Phenanthroline.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with 1,10-Phenanthroline.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with 1,10-Phenanthroline.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with 1,10-Phenanthroline.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with 1,10-Phenanthroline.Approved
Fluticasone propionateThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Fluticasone propionate.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with 1,10-Phenanthroline.Approved, Investigational, Withdrawn
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with 1,10-Phenanthroline.Approved
GarlicThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Garlic.Approved, Nutraceutical
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with 1,10-Phenanthroline.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with 1,10-Phenanthroline.Investigational
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with 1,10-Phenanthroline.Approved
HydrocortisoneThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Hydrocortisone butyrate.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with 1,10-Phenanthroline.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.Approved
Indenolol1,10-Phenanthroline may increase the bradycardic activities of Indenolol.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with 1,10-Phenanthroline.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with 1,10-Phenanthroline.Experimental
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with 1,10-Phenanthroline.Investigational
Labetalol1,10-Phenanthroline may increase the bradycardic activities of Labetalol.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Landiolol1,10-Phenanthroline may increase the bradycardic activities of Landiolol.Investigational
Levobetaxolol1,10-Phenanthroline may increase the bradycardic activities of Levobetaxolol.Approved, Investigational
Levobunolol1,10-Phenanthroline may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Lobeline.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with 1,10-Phenanthroline.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with 1,10-Phenanthroline.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with 1,10-Phenanthroline.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with 1,10-Phenanthroline.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with 1,10-Phenanthroline.Vet Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with 1,10-Phenanthroline.Experimental, Investigational
Mepindolol1,10-Phenanthroline may increase the bradycardic activities of Mepindolol.Experimental
MestranolThe serum concentration of Mestranol can be decreased when it is combined with 1,10-Phenanthroline.Approved
MethacholineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Methacholine.Approved, Investigational
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
MethscopolamineThe therapeutic efficacy of Methscopolamine can be decreased when used in combination with 1,10-Phenanthroline.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with 1,10-Phenanthroline.Approved
MethylprednisoloneThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with 1,10-Phenanthroline.Approved
Metipranolol1,10-Phenanthroline may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with 1,10-Phenanthroline.Approved
Metoprolol1,10-Phenanthroline may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.Approved, Illicit
Mivacurium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.Approved, Vet Approved
Nadolol1,10-Phenanthroline may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with 1,10-Phenanthroline.Investigational
Nebivolol1,10-Phenanthroline may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with 1,10-Phenanthroline.Approved, Withdrawn
NeomycinThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Neomycin.Approved, Vet Approved
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Nicotine.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with 1,10-Phenanthroline.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with 1,10-Phenanthroline.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with 1,10-Phenanthroline.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with 1,10-Phenanthroline.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with 1,10-Phenanthroline.Investigational
Oxprenolol1,10-Phenanthroline may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with 1,10-Phenanthroline.Approved
ParomomycinThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Penbutolol1,10-Phenanthroline may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PethidineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pethidine.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
PhenobarbitalThe therapeutic efficacy of Phenobarbital can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Pilocarpine.Approved, Investigational
Pindolol1,10-Phenanthroline may increase the bradycardic activities of Pindolol.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.Approved
Platelet Activating Factor1,10-Phenanthroline may increase the bradycardic activities of Platelet Activating Factor.Experimental
Practolol1,10-Phenanthroline may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with 1,10-Phenanthroline.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with 1,10-Phenanthroline.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with 1,10-Phenanthroline.Approved, Investigational
PrednisoloneThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with 1,10-Phenanthroline.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with 1,10-Phenanthroline.Approved, Experimental, Investigational
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with 1,10-Phenanthroline.Approved
PromethazineThe therapeutic efficacy of Promethazine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Propafenone1,10-Phenanthroline may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with 1,10-Phenanthroline.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Propranolol1,10-Phenanthroline may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.Approved
QuetiapineThe therapeutic efficacy of Quetiapine can be decreased when used in combination with 1,10-Phenanthroline.Approved
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
Rapacuronium1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with 1,10-Phenanthroline.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with 1,10-Phenanthroline.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with 1,10-Phenanthroline.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with 1,10-Phenanthroline.Approved
Sotalol1,10-Phenanthroline may increase the bradycardic activities of Sotalol.Approved
St. John's WortThe metabolism of 1,10-Phenanthroline can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with 1,10-Phenanthroline.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with 1,10-Phenanthroline.Approved, Investigational
Talinolol1,10-Phenanthroline may increase the bradycardic activities of Talinolol.Investigational
Technetium Tc-99m oxidronate1,10-Phenanthroline can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Temsirolimus.Approved
Terbutaline1,10-Phenanthroline may increase the bradycardic activities of Terbutaline.Approved
Tertatolol1,10-Phenanthroline may increase the bradycardic activities of Tertatolol.Experimental
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with 1,10-Phenanthroline.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
Timolol1,10-Phenanthroline may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with 1,10-Phenanthroline.Approved
TipranavirThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with 1,10-Phenanthroline.Approved, Withdrawn
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with 1,10-Phenanthroline.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with 1,10-Phenanthroline.Approved, Investigational
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with 1,10-Phenanthroline.Approved
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with 1,10-Phenanthroline.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.Approved
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with 1,10-Phenanthroline.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with 1,10-Phenanthroline.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with 1,10-Phenanthroline.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with 1,10-Phenanthroline.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with 1,10-Phenanthroline.Approved
VareniclineThe risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.Approved
Food Interactions
Not Available

References

Synthesis Reference

Judith N. Burstyn, Omar Green, Bhavesh A. Gandhi, "BIS(2,9-DI-TERT-BUTYL-1,10-PHENANTHROLINE)COPPER(I) COMPLEXES, METHODS OF SYNTHESIS, AND USES THEROF." U.S. Patent US20080206890, issued August 28, 2008.

US20080206890
General References
Not Available
External Links
KEGG Compound
C00604
PubChem Compound
1318
PubChem Substance
46505260
ChemSpider
1278
BindingDB
50092158
ChEBI
44975
ChEMBL
CHEMBL415879
HET
PHN
PDB Entries
1lih / 2fu7 / 2lig / 5tso / 5vj5

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)117 °CPhysProp
boiling point (°C)> 300 °CPhysProp
water solubility2690 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.78HANSCH,C ET AL. (1995)
pKa4.27 (at 20 °C)ALBERT,A ET AL. (1948)
Predicted Properties
PropertyValueSource
Water Solubility0.132 mg/mLALOGPS
logP2.31ALOGPS
logP2.29ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area25.78 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity53.9 m3·mol-1ChemAxon
Polarizability19.26 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9879
Blood Brain Barrier+0.9825
Caco-2 permeable-0.5136
P-glycoprotein substrateNon-substrate0.6487
P-glycoprotein inhibitor INon-inhibitor0.8831
P-glycoprotein inhibitor IINon-inhibitor0.9805
Renal organic cation transporterNon-inhibitor0.7775
CYP450 2C9 substrateNon-substrate0.866
CYP450 2D6 substrateNon-substrate0.8486
CYP450 3A4 substrateNon-substrate0.7961
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6111
Ames testAMES toxic0.8512
CarcinogenicityNon-carcinogens0.9476
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity2.1323 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9681
hERG inhibition (predictor II)Non-inhibitor0.8708
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0fai-1900000000-8bf54d7a505254cd0f42
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-003r-1900000000-bf66a4d49c83dd24535e
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-003r-4900000000-e878f31ffa5b4af39dfd
Mass Spectrum (Electron Ionization)MSsplash10-001i-1900000000-e3edab983e41e183110a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-7bdef677e6a80f05aa75
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-555e8d3f751a47049c5a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-c48df88a05c1dbab0adc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-001i-0900000000-07ee18512e76f5b25dd1
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0fb9-0900000000-7a08b5b37861250df6bd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-94a0600a96f48f8aa145
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fc0-0900000000-0f2b71fb75d6e9f09b6c
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-29a83efe3a4c61b6e760
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-f6eedb340d4cf4ab269f
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-b8ee2e5a776aecb532ca
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-88682d0eaadc3985ae6f
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-5c3af3894358cf9d55fc
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-29a83efe3a4c61b6e760
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e7952d19ca3578ac4501
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e7952d19ca3578ac4501
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-62142b81fd0b92ba0c9d
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-9cbaa490715b11601fdc
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-7095641d365002c9b143
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-0f89-0900000000-c2a7113134a8fdaed496
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-0fb9-0900000000-b0fd72c65f3813200a20
MS/MS Spectrum - ESI-ITFT , positiveLC-MS/MSsplash10-004i-2900000000-4ffad714811e85731892
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e090efe0cddbe7929cb2
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-4fc72504435ed95451ac
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-ea4fdf798419a11217f2
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e090efe0cddbe7929cb2
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-e090efe0cddbe7929cb2
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-45485816bda8e7909167
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-faad3e6b74ee6ca53b6e
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-001i-0900000000-95bc3cc9f850ef71dcf8
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-0f89-0900000000-7898242f42f1312b948e
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-0fb9-0900000000-b850980e5765d03a2799
MS/MS Spectrum - APCI-ITFT , positiveLC-MS/MSsplash10-004i-2900000000-7ef9fd08d9b8abdebd80
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-2900000000-173c7b28196041ae8de1
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenanthrolines. These are aromatic polycyclic compounds containing the phenanthroline skeleton, which is a derivative of phenanthrene, and consists of two pyridine rings non-linearly joined by a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Phenanthrolines
Sub Class
Not Available
Direct Parent
Phenanthrolines
Alternative Parents
Quinolines and derivatives / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
1,10-phenanthroline / Quinoline / Benzenoid / Pyridine / Heteroaromatic compound / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenanthroline (CHEBI:44975) / a small molecule (O-PHENANTHROLINE)

Targets

Kind
Protein
Organism
Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720)
Pharmacological action
Unknown
General Function
Transmembrane signaling receptor activity
Specific Function
Receptor for the attractant L-aspartate and related amino and dicarboxylic acids. Tar mediates taxis away from the repellents cobalt and nickel. Unlike in E.coli tar, it does not mediates maltose t...
Gene Name
tar
Uniprot ID
P02941
Uniprot Name
Methyl-accepting chemotaxis protein II
Molecular Weight
59613.55 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Pseudomonas maltophilia
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Has a high activity against imipenem.
Gene Name
Not Available
Uniprot ID
P52700
Uniprot Name
Metallo-beta-lactamase L1
Molecular Weight
30800.635 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:50